We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear*
Monoclonal antibodies have received significant attention over the past month and we previously podcasted on antibodies that target SARS-CoV-2. In this episode, we review several recent studies on a different "mab", tocilizumab, which targets inflammation mediated by interleukin-6 that is overly ramped up.
We review:
Stone et al) ( RCT)
Hermine et al (RCT))
Salvarani et al.) (RCT)
STOP-COVID) (observational)
Show notes (references/graphics): FOAMcast.org)
Thanks for listening, Lauren Westafer and Jeremy Faust
